key: cord-0838922-kqlcsdle
authors: Zarubova, Jana; Zhang, Xuexiang; Hoffman, Tyler; Hasani-Sadrabadi, Mohammad Mahdi; Li, Song
title: Biomaterial-based Immunoengineering to Fight COVID-19 and Infectious Diseases
date: 2021-03-09
journal: Matter
DOI: 10.1016/j.matt.2021.02.025
sha: 45136a4511c0fd9d34fe20e8a4304a9660adf22c
doc_id: 838922
cord_uid: kqlcsdle

Infection by SARS-CoV-2 virus often induces the dysregulation of immune responses, tissue damage, and blood clotting. Engineered biomaterials from the nano to macro scale can provide targeted drug delivery, controlled drug release, local immunomodulation, enhanced immunity, and other desirable functions to coordinate appropriate immune responses and repair tissues. Based on the understanding of COVID-19 disease progression and immune responses to SARS-CoV-2, we discuss possible immuno-therapeutic strategies and highlight biomaterial approaches from the perspectives of preventive immunization, therapeutic immunomodulation, and tissue healing and regeneration. Successful development of biomaterial platforms for immunization and immunomodulation will not only benefit COVID-19 patients, but also have broad applications for a variety of infectious diseases.

In 2020, coronavirus disease 2019 (COVID-19) rapidly evolved into a global public health emergency. Coronavirus SARS-CoV-2 was identified as the causative virus of the COVID-19 pandemic, with a much higher infection rate than SARS-CoV of 2003. With over 80 million people infected and 1.7 million deaths globally as of December 2020, there is an urgent need for preventive measures and therapeutic treatments. Currently there is no effective therapy for COVID-19, and for those who recover from the disease, the repair of damaged tissues and organs is challenging. On the preventive side, although significant progress has been made in vaccine development, it is not clear whether a long-term immunity can be achieved.

SARS-CoV-2 gets into cells via the binding of its spike protein to angiotensinconverting enzyme 2 (ACE2) receptor, which is upregulated in lung epithelial cells with age. 1 The infection of lung tissue may cause overactive inflammatory responses, tissue damage, and the development of acute respiratory disease syndrome (ARDS). Innate immune cells like neutrophils and macrophages are recruited directly to the infection site and release cytokines to stimulate the adaptive immune responses, mediated by T and/or B cells. 2 In healthy people, this process is efficient enough to resolve the infection in a timely manner. However, a dysfunctional and dysregulated immune response to SARS-CoV-2 infection, characterized by monocyte hyperactivation and extensive macrophage/neutrophil infiltration, causes severe lung damage and systemic effects across the body like prominent lymphopenia. 3 Compared to patients with mild symptoms, patients in severe and critical conditions exhibit symptoms of hyperinflammatory cytokine storm. Elevated level of proinflammatory cytokines, namely interferon (IFN), tumor necrosis factor (TNF), interleukin-6 (IL-6), and IL-1β, impaired type I IFN responses, and a reduced production of IFN-β and IFN-α were identified in more severe patient groups. 3 Increased levels of hyper-inflammatory cytokines may also trigger septic shock associated multi-organ failure, which has been predominantly observed in elderly populations. 4 Moreover, antibody responses in COVID-19 patients often seem to be weak and short-lived, which is probably caused by dysregulated humoral immune induction and defective formation of germinal centers, where J o u r n a l P r e -p r o o f on potential foreign antigens and generating protective neutralizing antibodies as well as memory immune cells. While the development of vaccines has achieved significant progress, the role of biomaterials to elicit adequate immune reaction should not be neglected, especially for the maintenance of long-term immunity and the enhancement of immune responses in aging populations. Biomaterials can support and boost effective immune responses through stabilizing the antigen, organizing antigen presentation patterns, recruiting antigen-presenting cells (APCs), triggering pattern recognition receptors (PRRs), and/or delivering antigens to the lymph nodes. 15 Secondly, if individuals have already been infected, treatments can be categorized into either antiviral or immunomodulatory therapies based on targeting the viruses or the host immune system. According to the stage of disease progression and patient's immune response patterns, each strategy has its advantages. 16 Viruses typically induce delayed, ineffective or dysregulated host immune system reactions.

Boosting host antiviral responses with IFN treatments and/or reducing viral load by antivirals represent potential treatments for the early stage of infection. 17 As the infection progresses and host cells actively respond to the virus, the buildup of a highly inflammatory environment can subsequently trigger cytokine storm. To mitigate an overwhelming immune response, immunomodulators can be used to minimize pathological damage and guide desirable cellular immunity to attack infected cells.

Some examples of therapeutic approaches that may support proper immune responses are anti-inflammatory agents (i.e., IL-6 blocker Tocilizumab), immunosuppressive drugs (i.e., glucocorticoids), checkpoint inhibitors (i.e., PD-1 inhibitor), and adaptive cell therapies.

Administration of small molecule antivirals or macromolecule biologics is usually systemic, however, and this global modulation of the immune system may be less specific and have side effects. Therefore, biomaterials can have an impactful role in both directing drug transport and realizing targeted or local immunomodulation.

Lastly, concerns related to the long-term side effects of COVID-19 infection on the large population of surviving patients have been raised. Following the clearance of a SARS-CoV-2 infection, the modulation of the immune environment in a tissue-specific J o u r n a l P r e -p r o o f manner with biomaterials can be used to support healing and regeneration of damaged tissues to prevent future complications.

In this review, we will focus on biomaterial-based immunoengineering approaches to tackle a variety of pathological problems during different stages of COVID-19 and infectious diseases. Figure 1 depicts the three major stages (vaccine prevention, drug delivery for therapies, and tissue healing and regeneration) where immunomodulation can have significant impact, and outlines the overall strategies at each stage of disease progression.

Effective vaccines induce long-term antigen-specific responses by developing long-lived memory T and B cells in addition to plasma cells, which produce antibodies.

Variables such as the type of vaccine and nature of the targeted pathogen define the extent of contribution for each of these immune cells. Vaccine development normally takes 10 to 15 years, where the optimal antigen is selected, the vaccine composition is optimized based on the preclinical animal studies, and 3 phases of clinical studies are performed to evaluate the safety and efficacy of the vaccine candidate. Accelerating COVID-19 vaccine development to condense 15 years into 15 months is very challenging not only because it is not known which immunogen and which vaccine type will be the most effective in establishing robust long-term immunoprotection, but also due to concerns about the adverse effects that the vaccine might potentially have on vulnerable individuals. One of the vaccine safety concerns is connected to a phenomenon termed antibody dependent enhancement (ADE). 18 Instead of inducing neutralizing antibodies that appropriately block a viral entry to the cells, a vaccine might induce the production of non-neutralizing antibodies that facilitate viral interactions with host cells to enhance inflammation and immunopathology. Previous studies on SARS-CoV or MERS-CoV showed that ADE was mainly associated with Th2-biased responses. Therefore, adjuvants promoting Th1 immune responses were preferred when designing COVID-19 vaccines. Other than safety, vaccines in clinical trials must also be effective. The levels of neutralizing antibodies as well as T cell responses, J o u r n a l P r e -p r o o f which play an important role in the immune protection against SARS-CoV-2, are evaluated to indicate vaccination efficacy.

Currently, there are more than 60 vaccines against COVID-19 in clinical trials and over a hundred of vaccines in pre-clinical phases. 19 Vaccine formulations range from weakened and replicating viruses to inactivated viruses, viral protein subunits, peptides, as well as genetic materials (i.e., DNA and RNA) (Figure 2) . Weakened virusbased vaccines are still live viruses, so they can trigger the strong immune responses but require challenging development and optimization to eliminate potential risks. Some COVID-19 vaccine frontrunners are based on inactivated viruses, which are produced through established chemical or heat treatment. 20 Inactivated virus vaccines from Sinopharm and Sinovac Biotech were already approved for emergency use in China.

Protein-based vaccines can be manufactured using a variety of platforms, such as the forced expression of viral proteins in mammalian, bacterial, or yeast cells in bioreactors. These techniques are well-developed in pharmaceutical industries but are limited by high costs associated with low-yield and essential multi-stage purification of possible (human) pathogen contamination. Therefore, cost and ease of manufacturing and scale-up should be considered for the global-scale production of potential vaccines.

Thus, an alternative method of cell-free production of peptides might be more appropriate; peptide-based vaccines are easier to design, optimize, manufacture, and scale up to meet the required worldwide mandate. Last but not least, recent clinical data shows a great promise on a relatively new class of vaccination by delivering genetic materials like DNA and RNA that induce a host production of immunogenic proteins in situ. For example, the two vaccines from Pfizer-BioNTech and Moderna have been approved by FDA for emergency use, and both of them use messenger RNA (mRNA) for viral protein expression. 21 Several other leading COVID-19 vaccines (i.e., Oxford-AstraZeneca, Johnson&Johnson, CanSino) are made from segments of viral DNA, which is packaged inside adenovirus for delivery into host cells. Recently, similar adenovirus-based vaccine has been approved for Ebola. RNA-and DNA-based vaccines can tackle the common issues with scalability, flexibility, and speed of vaccine production against any new pathogens. A major advantage of mRNA vaccines is that mRNA does not need to get into a nucleus as DNA and can be directly translated into J o u r n a l P r e -p r o o f proteins within the cytoplasm, which results in higher expression efficiency. 20 Compared to RNA-based vaccines, DNA-based vaccines have the advantage of being more stable.

Thus, due to the fragility of RNA, cold chain (-80°C) is usually required for vaccine delivery and storage.

Subunit vaccines containing purified antigens derived from pathogens are often weakly immunogenic. Without an adjuvant delivery system, subunit proteins or genetic materials are usually subjected to dissociation and elimination before entering host cells. 22 Adjuvant supplementation can enhance the magnitude and durability of immune responses and permit significant dose sparing. Adjuvants are mainly supposed to increase the immune cell recruitment and the production of inflammatory cytokines, enhance antigen uptake and presentation, and also facilitate antigen transport to the draining lymph node to promote the expansion and differentiation of the appropriate T and B cells (Figure 3) .

The most commonly used molecular adjuvants are ligands for pattern recognition receptors, such as Toll-like receptors (TLRs), nucleotide binding oligomerization (NOD)like receptors, retinoic acid inducible gene 1 (RIG-I)-like receptors, and C-type lectin-like receptors, which are expressed on the cell surface or in endosomal compartments of innate immune cells. These receptors recognize conserved pathogen-associated molecular patterns (PAMPs), such as dsRNA (TLR3), lipopolysaccharide (TLR4), ssRNA (TLR7/8), or unmethylated CpG motifs present in bacterial DNA (TLR9). 23 PAMP recognition by innate immune cells leads to the activation of different immune pathways, including inflammasome, complement, and/or NF-κB pathway, which can stimulate the adaptive immune system but may also cause excessive inflammation and toxicity. It is therefore critical to carefully select the adjuvant to induce appropriate type of immune responses to achieve effective vaccination.

Besides pathogen-derived molecules, immunostimulatory adjuvants can be derived from plants. Saponins are steroidal or triterpene glycosides, which can bind to specific carbohydrate receptors on the surface of APCs and promote their activation and production of pro-inflammatory cytokines. Saponins might also interact with J o u r n a l P r e -p r o o f cholesterol and facilitate endosomal escape and cross-presentation of antigens and thus activation of CD8 T cells. 24 Saponins containing aldehyde and ketone groups also form imines or Schiff bases with amino groups of receptors on the surface of T cells and serve as co-stimulatory signals for T cell activation. 24 COVID-19 candidate from Novavax uses Matrix-M TM , which is nanoparticle adjuvant composed of saponin together with cholesterol and phospholipid, for their protein-based vaccine and achieved high level of antibody production in early clinical trials. 25 26 Moreover, heat-shock proteins (HSPs) with bound antigenic peptides can be utilized as adjuvants to stimulate immune responses. 27 These molecular chaperones enhance both humoral and cellular immune responses by promoting the inflammatory cytokine secretion and facilitating antigen cross-presentation by DCs leading to the increased activation of CD8+ T cells. 28 Immunostimulatory cytokines such as IL-2, IFN-γ, IL-12, and granulocytemacrophage colony stimulating factor (GM-CSF) are also studied for their adjuvant function. 29 GM-CSF 30 , for example, promotes the recruitment, maturation, and antigenpresentation by dendritic cells (DCs) and elicits potent immune responses. Soluble, encapsulated, or conjugated administration of these reagents have been tested so far.

Lately, lipophilic statin drugs and small molecules called bisphosphonates have been discovered to have potent adjuvant activities. Bisphosphonates have been extensively used for the treatment of bone resorption diseases, such as osteoporosis. It is shown that they can also inhibit the mevalonate pathway in APCs 31 , which results in reduced lipidation of small GTPases, prolonged antigen presentation, increased T cell and B cell expansion, and antibody production. 32 In one study, the incorporation of bisphosphonates in nanoparticles was used to increase the targeting of bone metastatic breast tumors in mice 33 , however, its impact on modulating the therapeutic effects upon its interaction with immune cells has not been explored before.

However, molecular adjuvants can diffuse easily to the blood, which absorbs 10 times more fluid than the lymph, to cause systemic inflammation or toxicity. Therefore, these adjuvants are often combined with other (bio)materials, namely nanoparticles or liposomes, to improve localization, safety, and efficacy. The size of the particulate adjuvant is an important factor, which can shape the extent of immune response and J o u r n a l P r e -p r o o f vaccine protective efficacy. Small molecules drain to the blood, while particles approximately 9 to 100 nm preferentially enter the lymphatics and can get directly to the lymph node for antigen presentation. On the other hand, larger particles (0.5-2 μm) need to be transported to the lymph node by other cells, such as macrophages. 34 These size limits, however, can be altered by the mechanical properties of the particles. It has been shown that the optimal size for the efficient lymph node uptake is around 50 nm for rigid nanoparticles while for liposomes it is 150-200 nm. 35 Moreover, the size of immunomodulatory compounds can affect receptor cross-linking on the surface of immune cells or alter the uptake and intracellular processing of the antigen.

Besides the size, the particle charge can affect the immune cell responses.

Positively charged particles are more internalized by APCs compared to neutral or negatively charged particles and are able to induce higher innate and adaptive immune reactions. 36 Moreover, positively charged particles increase the antigen escape from endosomes and consequently cross-presentation of the antigen by APCs to CD8 T cells. 37 For a long time, alum (aluminum hydroxide and aluminum phosphate) was the only approved adjuvant in the USA. These nanosized crystals can adsorb antigens and aggregate into larger gel clusters upon hydration. 38 The binding of the antigen to alum particles is required for optimal immune responses. This mechanism is based on the electrostatic interaction of negatively charged antigen to the positively charged aluminum hydroxide as well as ligand exchange reactions between antigen phosphate groups and alum hydroxyl groups. 39 Moreover, adsorption of antigen to alum particles slows the antigen intracellular decay and thus prolongs the presentation by APCs. 40 Alum adjuvant ability is often attributed to the establishment of an antigen depot, however, the induction of local production of pro-inflammatory factors, which recruit neutrophils, monocytes, DCs, and macrophages, seems to be the main mechanism of action. 41 Oil-in-water nano-emulsions, such as MF59, which is composed of small squalene oil droplets (around 160 nm in diameter) stabilized by two non-ionic surfactants Span 85 and Tween 80, can elicit even stronger immune responses than alum. The MF59 immune stimulatory capacity relies on the fully formulated emulsion to J o u r n a l P r e -p r o o f recruit and activate APCs, as any of the individual components alone were not able to induce comparable immune responses. 42 Liposomes are another common type of particulate adjuvant, which can enhance immune responses even more robustly than the oil-in-water formulations. For example, the adjuvant system AS01, which can induce strong humoral and cellular immunity, is composed of liposomes of 50-100 nm in diameter from dioleoylphosphatidylcholine, cholesterol with TLR4 agonist monophosphoryl Lipid A (a detoxified derivative of lipopolysaccharide), and a saponin QS21. Cholesterol is included in the formulation mainly to reduce the cytotoxic activity of QS21, which would otherwise make holes in cell membranes. 43 Chitosan produced by partial deacetylation of the natural polysaccharide chitin, can also be utilized as an adjuvant, vaccine stabilizer, or delivery system. 44 This positively charged polymer has strong mucoadhesive properties and exhibits a range of immunological effects from the stimulation of inflammasome to enhanced antibody production and T cell responses. It acts through the binding to cell surface receptors, including macrophage mannose receptor and TLR-2. Internalized chitosan induces mitochondrial stress, the production of ROS, and subsequent release of the mitochondrial DNA to the cytosol. This process activates the STING pathway, which responds to the presence of DNA in the cytosol, to induce innate and adaptive immune responses. 45 Microparticles composed of plant-derived polysaccharide delta inulin with alginate trigger complement activation and, when co-administered with antigen, help mount a robust antigen-specific adaptive immune response consisting of both antibody and cell-mediated immunity. 46 Short synthetic peptides, which can self-assemble into long nanofibers, can also be used as adjuvants when coupled to antigenic peptides. The density of T and B cell epitopes displayed on the fibrils can be adjusted to raise optimal adaptive immune responses with minimal local inflammation. 47 This nanofiber vaccine can be administered intranasally to promote expansion of tissue-resident immune cells. 48

The level of immune responses toward vaccination can also be significantly J o u r n a l P r e -p r o o f affected by the route of administration. While most vaccines are injected intramuscularly, subcutaneous delivery with microneedle patches and pulmonary delivery with ventilators are promising alternatives (Figure 4) . Biodegradable or dissolvable microneedles provide minimally invasive transdermal delivery and can be as effective as the conventional injection for influenza. 49 Microneedle-based delivery of Hepatitis B and Influenza vaccines, prepared with silicon crystal or gelatin formulations respectively, are currently under clinical evaluation. 50 There are recent reports on developing SARS-CoV-2 vaccines that utilize microneedles to deliver spike proteins in mice. 51 Microneedle platforms can be fabricated using low-cost and scalable manufacturing techniques and may be suitable for global self-administration. This would be a convenient way to distribute vaccines for pandemics like COVID-19 if the mass production of a formulation can be achieved. Moreover, pulmonary administration empowers respiratory mucosal immunization and can be achieved using a wide range of mucoadhesive nanoparticles.

Nasal delivery of inhalable nanoparticulate powders is recently gaining research attention, particularly in vaccine applications, systemic drug delivery for the treatment of pain, and non-invasive brain targeting. 52 Interestingly, recent work has adapted this technology to deliver therapeutic peptides, which demonstrates feasibility for the delivery for antigen peptides. 53 The ability to train the immune system at the site of viral entry may be very promising for acute or chronic respiratory infections. In this scenario, T cells can better home to both the lung interstitium and airway lumen, whereas intramuscular immunization-activated T cells are not due to entrapment within the pulmonary vasculature. 54 Some studies have also shown the benefits of having local presence of immune cells at the mucosal layer. For example, pulmonary delivery of tuberculosis vaccine increases antigen transport to draining lymph nodes and elicits antigen-specific mucosal memory. 55 Lymphatics targeting

The lymphatics system is where immune cells are transported and memory cells are generated. Targeting the secondary lymphatic organs, such as spleens and lymph nodes, can improve the efficacy of vaccine and provoke desirable immune responses.

To achieve required spatiotemporal delivery and presentation of antigens and J o u r n a l P r e -p r o o f immunomodulatory cues, biomaterials can be designed to enhance lymphatic targeting and generate desirable populations of immune cells with minimal off-target side effects ( Figure 4) . Biomaterials can be engineered with physical and chemical properties such as particle size, charge, shape, composition and even more complicated stimuliresponsive designs.

Simple targeting to draining lymph nodes depends largely on particle size, while more sophisticated complexes are required to integrate into endogenous lymph transport processes. 56 One approach is to utilize carrier proteins such as the endogenous and most abundant serum protein albumin for longer circulation, improved stability, and better immunogenicity. Modifying vaccine adjuvant CpG oligonucleotides with a lipophilic albumin-binding tail can spontaneously form micelles, which can hitchhike albumin. Combined with the conjugation of an antigen peptide to an albuminbinding domain, this strategy increases lymph node accumulation and shows 30-fold increases in T cell activation. 57 Instead of albumin hitchhiking, the direct fusion of an antigen peptide to albumin reduces systemic circulation and improved proteolytic stability, as fused proteins traffic to the lymph nodes or are captured by local APCs. 58 With optimized factors, this approach improves vaccine immunogenicity by up to 90-fold and maximizes the responses to viral antigens. 58 SARS-CoV-2 proteins or peptides can be modified with an albumin-binding domain or fused to a carrier protein for LN targeting.

Elicio Therapeutics repurposed this type of platform and showed an improvement in SARS-Cov-2 specific cellular and humoral immune responses in mice. 59 Optimal activation of humoral immune responses also relies on appropriate antigen presentation to B cells. 60 To enhance B cell receptor engagement, lipid-based particles can be used as the base platform with the addition of monophosphoryl lipid A (MPLA) as an immunostimulatory adjuvant. As simple liposomes are relatively fragile, methods have been developed to extend the lifetime and stability of synthetic vesicles.

Polymeric cores of poly(lactide-co-glycolide) (PLGA) enveloped by PEGylated phospholipid bilayers provide support for the lipids and trigger strong antigen-specific IgG production. 61 Another approach was to engineer interbilayer-crosslinked multilamellar vesicles (ICMV). These vesicles benefit from stabilized lipids due to the crosslinking of headgroups of adjacent lipid bilayers. These ICMV loaded with antigen J o u r n a l P r e -p r o o f cargos are slow to degrade in serum but are susceptible to lipase within intracellular compartments, thus inducing potent T cell and antibody responses. 62 Another category of vesicles to achieve organized antigen presentation is self-assembling nanoparticles.

An early study using the glycoprotein of vesicular stomatitis virus (VSV-G) as an antigen has indicated that B cells respond promptly to highly organized VSV-G but are unresponsive to a poorly organized form of the same antigen. 63 Recently, selfassembling melittin-lipid nanoparticles were developed for LN-targeting, which elicited activation of APCs in LNs and led to a 3.6-fold increase in antigen-specific CD8 + T cell responses compared to free melittin. 64 Moreover, inspired by viral self-assembling envelope and capsid proteins, virus-like particles (VLPs) arrange immunogens in organized arrays on multivalent nanoparticles. Highly organized display platforms utilize symmetric cage-forming macromolecules, like enzyme lumazine synthase, ferrintin, or self-assembling nanoparticles, to form oligomers. 65 Unlike monomeric antigen, VLPs made of HIV envelope trimer (gp140 trimer) and glycoprotein 120 (gp120) were shown to increase shuttling to follicular dendritic cells (FDCs), concentrate at germinal centers, and enhance B cell activation. 66 The glycosylation helps antigen uptake through an innate immunity-mediated recognition pathway. 66 In addition, more sophisticated nanostructures like DNA origami nanoparticles have been recently designed for nanoscale antigen presentation. Antigen copy number, spacing, affinity, dimensionality, and rigidity of the scaffold were optimized for HIV gp120 to drive functional B cell responses. 67 Furthermore, another research group has used the receptor-binding domain (RBD) of Middle East respiratory syndrome-coronavirus (MERS-CoV) fused with RNA interaction domain and ferritin to construct a self-assembling, protein-folding vehicle. 68 Such VLPs can also be designed with SARS-CoV-2 protein components for the optimal vaccination. These approaches will provide tools for rapid clinical translation of potent and tissue-specific platforms for modulating pathogen-specific immunization. Recent pioneering work highlights the importance of materials design on nanoparticle-based antigen delivery platforms to generate specific T cell responses. 69 For instance, the presentation of the same antigen (ovalbuimin; OVA peptide) using two nanoscale delivery platforms can regulate distinct T cell fates in mice. In this case, redox-sensitive Last but not least, targeting lymph node for efficient B cells activation could be through a multistage delivery process. While there is a size preference for lymph node drainage, nanoparticles are still too big to access intra-lymph node canals. Therefore, combinations of nanoparticles and the controlled release of small molecule cargos via programmed degradable linkers creates a two-step platform to deliver molecules inside the lymph reticular network. 71 Such advanced delivery platforms are able to consider the physiological location of certain immune responses and indicate a path to precision medicine.

Besides developing particulate platforms to target secondary lymphoid or immunocompetent tissues, biomaterials can be used to create temporary lymph nodelike depots to induce immunity against viral infections. Such platform should be implantable via either injection or surgical placement while being biocompatible with a controlled biodegradation rate. These macroscale therapeutic devices can be placed at target sites to precisely manage the presentation of antigens and adjuvants, lower required dose to reduce cost, improve therapeutic efficacy, and limit systemic exposure.

The main function of such a construct will be the recruitment of adaptive or innate 

The challenge of COVID-19 treatments, among other viral infections, is the balance between anti-viral (preventing viral replication, expediting viral clearance, and boosting immune responses) and anti-inflammatory therapies (preventing the exacerbation of cytokine storm that can lead to systemic complications). 78 Repurposed malaria drugs that interfere with viral entry and propagation, such as is currently recommended to prevent thrombotic complications. 79 However, some COVID-19 patients still developed thrombosis despite prophylaxis with LMWH. 80 Therefore, anti-complement drugs, such as narsoplimab (monoclonal antibody against MASP-2) 81 or eculizumab (monoclonal antibody that blocks complement protein C5) 82 have been tested and showed promising results in reducing endothelial damage and thrombotic risk.

The treatments that are currently under evaluation in clinical trials have been covered in recent reviews. 83 However, these platforms are typically delivered systemically making the balance between viral clearance and prevention of overactive immune responses difficult. Combinations of known and clinically approved therapeutics with material and/or cell-derived components may serve to enhance treatment efficacy through localized delivery and tuned mechanisms. In this way, anti-viral or immunotherapeutic regiments can be based on disease trends, such as accumulation in tissues with high ACE2 expression or tissue-specific disease states.

The direct targeting of sites of high virus titers and immune cell accumulation should be able to enhance the antiviral effects and immunomodulation of existing therapies. Even though COVID-19 is primarily a respiratory disease, the sites of infection are not limited to the lungs. The impairment of cardiovascular function and various coagulation disorders in COVID patients are a result of the wide distribution of ACE2 receptors and expansion of viruses within the endothelium and vascular smooth muscle cells. 84 Here we will focus on the strategies to target drug delivery to the lung and cardiovascular systems that are typically inflamed as a result of a SARS-CoV-2 infection.

Firstly, biomimetic particles modified with targeting ligands or antibodies against adhesion molecules expressed on the inflamed tissue can be used for specific drug targeting. The ability to tailor the activity of the immune system, both activation and reduction, may prove efficacious in viral clearance and preventing tissue damage.

These techniques are not directly related to the delivery of immunotherapies; however, J o u r n a l P r e -p r o o f the modularity of peptide or protein modifications can be easily adapted for novel therapeutic strategies. To resolve inflammatory signaling of blood vessels, one approach involves the delivery of antioxidant enzymes. The delivery of these enzymes alone lacks stability and targeting to achieve functionality at the site of inflammation. To solve this issue, an antioxidant mimetic (EUK-134) may be loaded into PEGylated liposomes conjugated to anti-PECAM-1 antibodies to improve drug stability and specifically target pulmonary ECs; this biomaterial formulation retained enzyme functionality, enhanced desired lung biodistribution, and protected against pulmonary vascular edema in an LPS-induced mouse injury model. 85 Lungs are highly inflamed during ARDS so the local environment is usually acidic and populated with adhesion molecules like intercellular adhesion molecule-1 (ICAM-1) to attract monocytes and lymphocytes. It has been reported that the use of anti-ICAM-1 antibody coated poly(βamino ester)/PEG nanoparticles enhances lung targeting and can release antiinflammatory agents. 86 In this formulation, the incorporation of acid-sensitive poly(βamino ester) domains enables pH-dependent release of drug cargo within acidic, inflamed lungs, which improves the efficacy of TPCA-1 treatment in a murine acute lung injury model, compared to free drug or untargeted drug-loaded nanoparticles. Other strategies to target inflamed vasculature include the conjugation of integrin LFA-1L domain, which binds to ICAM-1, or antibodies against E-selectin to the surface of particles or liposomes (regardless of drug cargo or material). 87 Alternatively, targeting ligands can be replaced with peptides such as VHPKQHR 88 for VCAM-1-binding or Cyclo(1,12)PenITDGEATDSGC (cLABL) peptide for high affinity ICAM-1 binding. 89 Similar targeting strategies can be utilized to selectively deliver thrombolytic agents to treat thrombosis and embolism. For example, a modified fibrin-homing peptide (allyl-GGCR(NMe)EKA) has been used to target microenvironment-sensitive nanogels to the blood clots. 90 The acrylamide nanogels contain thrombin-sensitive crosslinkers, which enabled high intra-clot release of encapsulated thrombin inhibitor hirudin. These nanogels showed increased circulation time and bioavailability compared to hirudin alone and were able to efficiently prevent and inhibit clot formation in mouse models of pulmonary embolism and thrombosis. Another strategy for targeted drug release is based on the increased concentration of hydrogen peroxide by activated platelets at the J o u r n a l P r e -p r o o f site of thrombus formation. H 2 O 2 -responsive boronate particles show site-specific release of an anti-platelet drug and potent thrombolytic and anti-inflammatory activity without adverse side effects. 91 Further approaches in biomaterial design for thrombosis can be found in a recent review. 92 The lungs possess a unique characteristic of dense capillary networks, which are quite narrow and can only pass one red blood cell (RBC) at a time. Attachment of synthetic nanoparticles onto RBC surface creates a cell hitchhiking platform where nanoparticles are sheared off when squeezing through these narrow capillaries. 93 Non-covalent attachment of nanoparticles to RBCs increases lung accumulation while reducing uptake in other organs such as liver, spleen, and brain. 94 If combined with anti-ICAM-1 strategies, lung retention of nanoparticles is further improved. 95 Interestingly, by tuning the affinity of nanoparticles to RBCs and making them shear-resistant, the target site can be shifted to the spleen where lots of APCs reside. Erythrocyte-driven immune targeting (EDIT) has been developed as a vaccine platform, where erythrocytes deliver antigens selectively to the lung or spleen tissues. 96 This process mimics the natural capture of pathogen by erythrocytes and may not need additional adjuvants to elicit a strong immune response. 96 Lastly, the capacity of SARS-CoV-2 to infect the heart necessitates cardiac tissue targeting for treatments. The use of a cardiac targeting peptide (CTP) 97 and the CRPPR peptide 98 enhance the delivery and retention of an imaging agent or liposomes, respectively. Additionally, a CTP fused to a membrane protein of EVs improves cardiomyocyte cellular uptake in vitro and demonstrates enhanced retention following intramyocardial injection. 99 For protein therapeutic delivery, tannic acid modifications induce aggregation and enhance cardiac tissue accumulation of peptides, viruses, and proteins following intravenous injection; an intravenous treatment of modified-bFGF promotes cardiac recovery, compared to a direct injection of unmodified bFGF, in an in vivo model of myocardial ischemia. 100 The presence of markers of tissue damage can also be used as a signal to influence the accumulation of nanoparticles. In one approach, polynorbornene nanoparticles with incorporated MMP-2 and MMP-9 recognition peptides, preferentially aggregate based on matrix metalloprotease (MMP) activity. This interesting approach uses particles <100 nm that can diffuse through leaky vasculature to sites of myocardial damage but do not typically persist within the tissue J o u r n a l P r e -p r o o f for long periods of time. The programmed accumulation enables localization and retention up to 28 days at the site of tissue injury. 101 Since MMPs are present during the remodeling phase following acute injury and may be involved in SARS-CoV-2 infections, potentially serving as a target to deliver antiviral or immunomodulatory compounds. 102

Neutrophils, the most abundant white blood cells in the body, reside in high numbers in the lungs and are the first line of defense against invading pathogens. Upon encountering danger signals, neutrophils quickly migrate to the targeted tissue and release immunomodulatory molecules, which recruit and activate other immune cells.

They also internalize pathogens and destroy them in organelles called phagosomes.

Moreover, neutrophils can eliminate the invaders by releasing reactive oxygen species and granules containing enzymes and antimicrobial peptides or they can prevent the spreading of pathogens by ensnaring them in web-like structures of DNA and proteins named neutrophil extracellular traps (NETs). However, the accumulation and excessive activation of neutrophils, as in case of ARDS in COVID-19 patients, can lead to exacerbated tissue damage and increased risk of thrombosis. 103, 104 To mitigate acute inflammation, activated neutrophils can be selectively targeted with nanoparticles containing agglutinated 105 or denatured proteins 106 , which bind to Fcγ RIII receptors on activated neutrophils. 107 The feasibility of this approach is demonstrated with nanoparticles made from denatured albumin loaded with an antiinflammatory drug, which are preferentially internalized by activated neutrophils. In contrast, nanoparticles coated by natural albumin are ignored by neutrophils. This highlights the importance of nanoparticle design on generating specific immune responses. 108 Particulate therapeutics can also be used to suppress neutrophil recruitment and accumulation in inflamed tissues. Intravenously injected microparticles can be phagocytosed by circulating neutrophils, which triggers their apoptosis and elimination by the liver. Alternatively, particles captured in the liver and internalized by resident macrophages recruit circulating neutrophils. 109 In both cases, the administration of particles during acute inflammation can decrease the numbers of circulating J o u r n a l P r e -p r o o f neutrophils and/or change their homing site, which might be a useful strategy to mitigate inflammation.

In another strategy, cells can be equipped with "cellular backpacks", polymeric particles loaded with therapeutic agents, that can be attached to the cell membrane with the use of antibodies, cell-adhesive molecules, or by covalent binding to cell surface proteins. 110 The size and shape of polymeric particles can significantly affect cellular backpack stability, as flat disk-like particles are phagocytosed less than spherical particles. 111 In this way, immune cells, such as monocytes, 112 can be utilized to deliver cargo into inflamed tissues. Furthermore, particulate drug delivery systems can be coated with cell membranes derived from different cell types including platelets 113 or neutrophils, 114 which help reduce their immunogenicity and improve inflammationtargeting capabilities. RBCs and platelets can be fused to create hybrid-membrane cloaked nanoparticles, which show increased circulation half-life and improved homing to inflamed tissues owing to intrinsic RBC and platelet components, respectively. 115 Although adding such a feature seems interesting as it can represent the most natural biointerface, the translational and regulatory pathways appear unclear.

Besides coating nanoparticles or liposomes with cell membranes, extracellular vesicles (EVs) secreted by different cell types can be used to deliver drugs and vaccines, introduce targeting, or enhance regeneration. EVs are nanometer-sized phospholipid membrane-enclosed vesicles that contain bioactive components such as nucleic acids or proteins derived from their parental cells. Based on their surface markers, EVs can be preferentially internalized by distinct cell types and tissues comparably to the membrane-coated biomimetic particles. 116 Among the most studied EVs with pro-regenerative properties are vesicles derived from mesenchymal stem cells (MSCs). These EVs have powerful immunomodulatory effects, which can be beneficial in the treatment of various inflammatory diseases including ARDS. 117 118 EV content can also be modified through the genetic engineering of EV-secreting parental cells. For example, EV targeting efficiency can be increased by fusing targeting peptides or proteins with the C1C2 domain of lactadherin, which binds to phosphatidylserine that is strongly enriched in EV membranes. 119 The EV circulation half-life can be prolonged by overexpressing CD47, presenting a 'don't eat me' signal, that can protect EVs from being phagocytosed. 120 In addition to micro and nano particles, artificial cells can be utilized to perform more complex regenerative or immunomodulatory tasks. For instance, artificial 

In the previous sections, we have discussed the prevention of SARS-CoV-2 viral infection with vaccine supplements and the approaches to enhance viral clearance and mediate inflammatory-related symptoms at a systemic and tissue-specific level with immunotherapies. However, the long-term pathological effects of SARS-CoV-2 infection and the potential to exacerbate or induce future complications, even in mild cases, are just beginning to be explored. 125 A high correlation of symptom severity and mortality in patients with preexisting conditions sheds light on the potential risks of organ trauma. A buildup of fibrotic scar tissues causes many of the leading cardiac and pulmonary diseases, and COVID-19 induced tissue damage may contribute to their exacerbation.

The extent, location, and duration of potential tissue damage, as well as the risk of future complications, resulting from COVID-19 infection must be understood and treated accordingly to prevent future trauma in this extensive patient group.

To accomplish this, tissue damage resulting from COVID-19 infection and treatments can be retroactively understood through patient characterization and longterm follow up; however, this information may not be available in a timely manner.

Interestingly, tissue models may be adapted to predict at risk organ systems, determine the mechanism of pathogenesis, and screen potential therapies in a high-throughput fashion. In this section, we seek to address the long-lasting damage at a tissue-specific level and identify potential post-COVID treatments, specifically immunomodulatory biomaterial compositions, that may support healing and prevent future complications.

Several previously developed strategies demonstrate the key role of biomaterials for the targeted and responsive delivery of therapeutic molecules, co-localization of multiple factors, and the induction of specific immune response with relevance for COVID-19 therapeutic development 126 . We focus on the respiratory, cardiovascular, and nervous systems as they represent the primary and more severe long-term tissue damages in COVID-19 survivors. While our discussion focuses on immunomodulation for tissue healing and regeneration, many other widely explored tissue engineering approaches utilizing cell transplantation, scaffold engineering and drug delivery can also be applied and combined with immunotherapeutic strategies. 127, 126 J o u r n a l P r e -p r o o f The extent of prolonged lung dysfunction for COVID-19 survivors has begun to be evaluated, and is expected to pose major issues. 132 The presence of lung abnormalities scales with disease severity and persists even after the treatment and the resolution of symptoms. 133 Additionally, a study in April 2020 detected the presence of lung abnormalities via CT scans in asymptomatic COVID-19 positive patients. 134 This troubling discovery indicates the possibility that those unknowingly exposed to COVID-19 and asymptomatic may develop pulmonary fibrosis. An accumulation of scar tissue can lead to significant problems as it contributes to irreversible interstitial lung disease. 135 inflammatory cues into the microgels to induce intrinsic anti-inflammatory stem cell secretion while also protecting against rapid immune clearance. 143 As previously mentioned, cell-based backpacks, based on the homing of specific cell types to fibrotic markers, can also be used to deliver therapeutic payloads to reverse fibrotic scarring. 146 In this study, drug-loaded PLGA/PEG nanoparticles were conjugated to monocytes, which demonstrated MMP-2-induced release and lung injury-homing respectively. This formulation incorporates a multi-stage targeting and release cascade through specific cell or peptide conjugation to explicitly induce the internalization of astaxanthin/trametinib-loaded nanoparticles within injured alveolar epithelial cells to reverse fibrosis.

As a result of viral infection, cytokine storm, or antiviral treatments, both cardiac tissue and the vascular system may suffer from lasting damage. In cases of a direct viral infection of the heart, a chronic immune response is the main contributor to the degradation of ECM and induction of fibrosis. 147 Fundamentally, intrinsic heart healing is limited by the lack of cardiomyocyte proliferation and active remodeling processes. 148 Recent reviews have covered the specific mechanisms of COVID-19-induced cardiac damage and risks of long-term damage. 149 The prevalence and unknown duration of cardiovascular complications associated with COVID-19 represents an unmet clinical need; elevated levels of troponin, indicating the presence of acute cardiac injury, were found in 20-30% of hospitalized COVID-19 patients. 150 Cardiac swelling, scarring, reduced ejection fraction, and high troponin T levels remain even after COVID-19

recovery. 151 Initial studies have identified that markers of cardiac damage and inflammation can last up to at least 10 weeks after initial diagnosis. 152 One example utilizes a poly(ethylene argininylaspartate diglyceride) and heparin coacervate to locally co-deliver FGF-2 and IL-10 with an extended release profile.

Intramyocardial injection of this formulation enhances regenerative outcomes following myocardial infarction, compared to free protein or single protein coacervate delivery. 154 Macrophage polarization toward an M2 regenerative phenotype plays a key role in limiting the extent of tissue damage. In one approach, IL-33 overexpression vectors are delivered intravenously with polyethyleneimine. 155 This delivery mechanism, which utilizes polyethyleneimine complexed with DNA vectors to induce exogenous IL-33

expression, induces specific cell-secreted cytokines as an alternative to cytokine delivery. This treatment enhances the endogenous production of IL-4 and subsequent M2 macrophage polarization to improve myocarditis outcomes in a mouse model. An interesting strategy employs an injectable alginate-based hydrogel to deliver CSF-1 and IL-4 into the heart and demonstrates the potential to promote regenerative macrophages. 156 Recently, the role of B cells in exacerbating inflammation and reducing M2 polarization has been identified 157 ; treatments, such as Pirfenidone, to address this mechanism may serve as a potential therapeutic. 158 In addition, the role of autoimmunity, in which cardiac proteins can activate and sustain an adaptive immune response, in the context of tissue healing and regeneration has been highlighted. 159 SARS-CoV-2, like other viruses that induce myocarditis, triggers cardiac autoimmunity that prolongs tissue damage, which should be addressed by potential therapies. 160, 161 Along these aims, siRNA against CSF-1 is loaded in lipid nanoparticles and delivered intravenously in mouse models of virus-or autoimmune-mediated myocarditis. In both cases, the inhibition of CSF-1 reduces the infiltration of inflammatory monocytes into the heart and is sufficient to lessen the extent of tissue damage. 162 Interestingly, even with a reduced inflammatory response, viral clearance is not hindered.

Immune cells can also promote revascularization of affected tissues. Proinflammatory M1 macrophages are important at the beginning of angiogenic process, when they secrete pro-angiogenic factors like VEGF, 163 while M2 macrophages dominate at the later time points when they stabilize blood vessels and promote anastomoses. 164 Thus, immune-instructive biomaterials, which can guide the macrophage phenotype change by sequential release of multiple immunomodulatory factors, might be helpful for vascular regeneration. This strategy was used to promote angiogenesis and regeneration by initial release of IFN-γ followed by prolonged release of IL-4 from a decellularized scaffold.

Apart from macrophages, revascularization of damaged tissues can be enhanced by biomaterials concentrating pro-healing T cell subtypes. Animals previously vaccinated with an antigen and Th2 immune response-inducing adjuvant show enhanced vascularization and regeneration of ischemic tissue after receiving the same antigen released from biomaterial scaffold, which attracts and concentrates antigenspecific CD4+ Th2 T cells. 165

Like the aforementioned organ systems, the cells and structure of the central nervous system (CNS) is susceptible to viral infection and immunogenic collateral damage. 166 Human brain organoids have been utilized to characterize the invasion potential of SARS-CoV-2 and identify potential treatments, such as Sofosbuvir. 167 The 

The modulation of immune responses has great potential for the prevention and treatment of infectious diseases like COVID-19. However, conventional pharmaceutical interventions lack the spatiotemporal control for robust and precise immune activities.

Biomaterials create applicable platforms for enhanced immune responses upon vaccination, targeted and controlled drug delivery, local immunomodulation, and minimally invasive methods for drug administration. Biomaterial-based approaches to guide the immune system to fight viral infections and regenerate damaged tissue can be developed and adopted from other fields such as cancer immunotherapy and stem cell engineering. Because these platforms are not limited by the type of virus, new combinatorial treatments are valuable in creating more effective treatments for a variety of infectious diseases in any future epidemic or pandemic. Table 1 and Table 2 highlight examples of each biomaterial-based approach we discussed in this review for the improvement of preventative immunization, therapeutic treatments, and tissue healing and regeneration. In addition, biomaterials can have broad applications in many other aspects such as personal protection equipment, diagnosis devices, and organ-onchip disease modeling. 176 Regarding COVID-19, there are still more problems to be addressed using immunomodulatory interventions. As the risk for severe illness increases with age, a critical need is the modulation of the immune responses in senior populations. The homeostatic and regenerative capacity of T cells declines with age. Thymic T cell generation, T cell receptor (TCR) repertoire diversity, and the self-renewing potential of T cell populations reduce throughout the adult lifetime. 177 In addition, coronaviruses often cause reinfections, and it is not clear whether current vaccines are effective in inducing long-term immunity. 178 Therefore, building T memory cell populations via vaccines and promoting effective antigen-specific T cell clonal expansion upon infection are potential strategies to address weakened and insufficient immune responses.

Furthermore, due to the complexity of T cell interaction with MHC complexes, J o u r n a l P r e -p r o o f immunoinformatic studies using data science and machine learning approaches can facilitate the identification of potential B cell and T cell epitopes for peptide vaccine development. 179, 180 Besides the special consideration for the elderly population, the replication of viruses and increase in viral burden continually stimulate positive-feedback immune responses. This process may cascade into an overactive immune response that results in fatal conditions such as cytokine storms in some COVID-19 patients. Biomaterial composition or biomaterial-based drug delivery systems can be engineered with bioresponsive components, which can regulate biological processes and the location, timing, and release profile of drug cargo. 15 Integration of artificial intelligence (AI) at the development stage of biomaterial-drug formations can be utilized to determine optimal configurations for ideal release profiles and maximal therapeutic effects. 181 Additionally, AI can be used to expedite the development of the next-generation of immunotherapeutics through better design of biomaterials and predictions of cellspecific interactions, efficacy, or risk of adverse events. 182 The appropriate biomaterial strategy will enable the generation of desired immune responses to prevent or treat cytokine storm. In particular, nanomaterials have been implicated by others for their role in COVID-19 therapy due to their modular drug loading capabilities, delivery mechanisms, tissue targeting, and symptom relief. 108 Moreover, the transfer of biomaterial designs from bench to bedside is a practical issue, especially for infectious diseases. The scale-up feasibility and manufacturing costs should be taken into consideration while designing biomaterial products. The complexity and simplicity of a biomaterial solutions should be well balanced to enable both reliable clinical outcomes and easy mass production. In addition, the adaptation of biomaterials and/or drug formulations that have already been used in FDA-approved applications can reduce the regulatory burden and time of approval. Thus, building a history of using biomaterials for various applications will favor fast clinical approval upon an outbreak.

Finally, just as the use of biomaterials for infectious diseases utilizes strategies from other disciplines, biomaterial solutions that can modulate and balance J o u r n a l P r e -p r o o f inflammatory and anti-inflammatory responses to COVID-19 will also have translatable applications for cancer vaccines, chronic infections, and tissue repair. can be used to improve patient compliance as well as immunization efficacy. Nasal, pulmonary, intravascular, and subdermal immunizations can be performed through the use of nano-and microparticles, hydrogels, and microneedles. Biomaterials-based engineering strategies can be used to develop more effective vaccines. Particulate vaccines can be designed to drain efficiently to lymph nodes. Alternatively, the hydrogel/scaffold vaccine can act as temporary artificial lymph nodes to provide niches for immune cell programming.

SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues

The trinity of COVID-19: immunity, inflammation and intervention

2020) T cell responses in patients with COVID-19

Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages

Loss of Bcl-6-expressing T follicular helper cells and germinal centers in COVID-19

Endothelial cell infection and endotheliitis in COVID-19

Pericyte-specific vascular expression of SARS-CoV-2 receptor ACE2 -implications for microvascular inflammation and hypercoagulopathy in COVID-19. bioRxiv

The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management

Coagulation abnormalities and thrombosis in patients with COVID-19

Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study

Rationale for targeting complement in COVID-19

Multiple roles of complement MASP-1 at the interface of innate immune response and coagulation

Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation. medRxiv

2020) A materials-science perspective on tackling COVID-19

Respiratory virus infections: Understanding COVID-19

Interferons: success in anti-viral immunotherapy

Activation of JUN in fibroblasts promotes profibrotic programme and modulates protective immunity

The COVID-19 vaccine development landscape

COVID-19 Vaccine Frontrunners and Their Nanotechnology Design

Communicating Effectively About Emergency Use Authorization and Vaccines in the COVID-19 Pandemic

Better Adjuvants for Better Vaccines: Progress in Adjuvant Delivery Systems, Modifications, and Adjuvant-Antigen Codelivery

Use of defined TLR ligands as adjuvants within human vaccines

Elucidating the mechanisms of action of saponin-derived adjuvants

Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine

Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice

A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides

Heat shock proteins: linking danger and pathogen recognition

Vaccine Strategies to Improve Anti-cancer Cellular Immune Responses

GM-CSF-based cancer vaccines

The Mevalonate Pathway Is a Druggable Target for Vaccine Adjuvant Discovery

Bisphosphonates target B cells to enhance humoral immune responses

On-chip synthesis of fine-tuned bone-seeking hybrid nanoparticles

Synthetic Nanoparticles for Vaccines and Immunotherapy

Liposomal vaccines incorporating molecular adjuvants and intrastructural T-cell help promote the immunogenicity of HIV membrane-proximal external region peptides

Integrating Biomaterials and Immunology to Improve Vaccines Against Infectious Diseases

Rational Design of PLGA Nanoparticle Vaccine Delivery Systems To Improve Immune Responses

Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want

Turning the Old Adjuvant from Gel to Nanoparticles to Amplify CD8+ T Cell Responses

Alum increases antigen uptake, reduces antigen degradation and sustains antigen presentation by DCs in vitro

Vaccine priming is restricted to draining lymph nodes and controlled by adjuvant-mediated antigen uptake

The adjuvant effect of MF59 is due to the oil-in-water emulsion formulation, none of the individual components induce a comparable adjuvant effect

Adjuvant system AS01: helping to overcome the challenges of modern vaccines

Carbohydrate-based immune adjuvants

The Vaccine Adjuvant Chitosan Promotes Cellular Immunity via DNA Sensor cGAS-STING-Dependent Induction of Type I Interferons

Advax™, a novel microcrystalline polysaccharide particle engineered from delta inulin, provides robust adjuvant potency together with tolerability and safety

Titrating T-Cell Epitopes within Self-Assembled Vaccines Optimizes CD4+ Helper T Cell and Antibody Outputs

Adjuvant-free nanofiber vaccine induces in situ lung dendritic cell activation and T<sub>H</sub>17 responses

Microneedle-based vaccines. Vaccines for Pandemic Influenza

The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo-controlled, phase 1 trial

Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development

Inhalable nanoparticulate powders for respiratory delivery

Inhalation of peptide-loaded nanoparticles improves heart failure

Mucosal immunity and novel tuberculosis vaccine strategies: route of immunisationdetermined T-cell homing to restricted lung mucosal compartments

Generation of effector memory T cellbased mucosal and systemic immunity with pulmonary nanoparticle vaccination

From sewer to saviourtargeting the lymphatic system to promote drug exposure and activity

Structure-based programming of lymph-node targeting in molecular vaccines

Pharmacokinetic tuning of protein-antigen fusions enhances the immunogenicity of T-cell vaccines

A lymph node-targeted Amphiphile vaccine induces potent cellular and humoral immunity to SARS-CoV-2

Shaping humoral immunity to vaccines through antigen-displaying nanoparticles

Robust IgG responses to nanograms of antigen using a biomimetic lipid-coated particle vaccine

Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses

The influence of antigen organization on B cell responsiveness

Melittinlipid nanoparticles target to lymph nodes and elicit a systemic anti-tumor immune response

Second career of a biosynthetic enzyme: Lumazine synthase as a virus-like nanoparticle in vaccine development

Innate immune recognition of glycans targets HIV nanoparticle immunogens to germinal centers

Role of nanoscale antigen organization on B-cell activation probed using DNA origami

Chaperna-mediated assembly of ferritin-based Middle East respiratory syndrome-coronavirus nanoparticles

Engineering approaches to immunotherapy

Tunable T cell immunity towards a protein antigen using polymersomes vs. solid-core nanoparticles

Programmable multistage drug delivery to lymph nodes

Scaffolds that mimic antigen-presenting cells enable ex vivo expansion of primary T cells

Single-shot Mesoporous Silica Rods Scaffold for Induction of Humoral Responses Against Small Antigens

Growth factors engineered for super-affinity to the extracellular matrix enhance tissue healing

Cytokine Secreting Microparticles Engineer the Fate and the Effector Functions of T-Cells

Mechanosensing through YAP controls T cell activation and metabolism

T-cell activation is modulated by the 3D mechanical microenvironment

Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review

Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

Endothelial injury and thrombotic microangiopathy in COVID-19: Treatment with the lectin-pathway inhibitor narsoplimab

Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: A proof-of-concept study

Potential treatments for COVID-19 related cytokine storm-beyond corticosteroids

Multiple organ dysfunction in SARS-CoV-2: MODS-CoV-2. Expert review of respiratory medicine

Endothelial targeting of liposomes encapsulating SOD/catalase mimetic EUK-134 alleviates acute pulmonary inflammation

) pH-responsive nanoparticles targeted to lungs for improved therapy of acute lung inflammation/injury

Biomimetic nanoparticles for inflammation targeting

Noninvasive Vascular Cell Adhesion Molecule-1 Imaging Identifies Inflammatory Activation of Cells in Atherosclerosis

PLGA Nanoparticle−Peptide Conjugate Effectively Targets Intercellular Cell-Adhesion Molecule-1

Self-regulated hirudin delivery for anticoagulant therapy

Fibrin-Targeted and H2O2-Responsive Nanoparticles as a Theranostics for Thrombosed Vessels

Nano-Medicine for Thrombosis: A Precise Diagnosis and Treatment Strategy

Erythrocyte leveraged chemotherapy (ELeCt): Nanoparticle assembly on erythrocyte surface to combat lung metastasis

Red blood cellhitchhiking boosts delivery of nanocarriers to chosen organs by orders of magnitude

Delivering nanoparticles to lungs while avoiding liver and spleen through adsorption on red blood cells

Erythrocyte-driven immunization via biomimicry of their natural antigen-presenting function

Cardiac Targeting Peptide, a Novel Cardiac Vector: Studies in Bio-Distribution

The cargo of CRPPR-conjugated liposomes crosses the intact murine cardiac endothelium

Exosomes Engineered to Express a Cardiomyocyte Binding Peptide Demonstrate Improved Cardiac Retention in Vivo

Targeting protein and peptide therapeutics to the heart via tannic acid modification

Enzyme-Responsive Nanoparticles for Targeted Accumulation and Prolonged Retention in Heart Tissue after Myocardial Infarction

Distinct and early increase in circulating MMP-9 in COVID-19 patients with respiratory failure

Neutrophils, Crucial, or Harmful Immune Cells Involved in Coronavirus Infection: A Bioinformatics Study

Targeting potential drivers of COVID-19: Neutrophil extracellular traps

Supramolecular Organization Predicts Protein Nanoparticle Delivery to Neutrophils for Acute Lung Inflammation Diagnosis and Treatment. bioRxiv

Neutrophil-Mediated Delivery of Therapeutic Nanoparticles across Blood Vessel Barrier for Treatment of Inflammation and Infection

Prevention of vascular inflammation by nanoparticle targeting of adherent neutrophils

Insights from nanotechnology in COVID-19 treatment

Neutrophil-Particle Interactions in Blood Circulation Drive Particle Clearance and Alter Neutrophil Responses in Acute Inflammation

Active targeting of chemotherapy to disseminated tumors using nanoparticle-carrying T cells

Role of target geometry in phagocytosis

Monocyte-mediated delivery of polymeric backpacks to inflamed tissues: a generalized strategy to deliver drugs to treat inflammation

Nanoparticle biointerfacing by platelet membrane cloaking

Nanoparticles Coated with Neutrophil Membranes Can Effectively Treat Cancer Metastasis

Erythrocyte-Platelet Hybrid Membrane Coating for Enhanced Nanoparticle Functionalization

Cell membrane-formed nanovesicles for disease-targeted delivery

Therapeutic Use of Extracellular Vesicles for Acute and Chronic Lung Disease

Active loading into extracellular vesicles significantly improves the cellular uptake and photodynamic effect of porphyrins

Exosome Display technology: applications to the development of new diagnostics and therapeutics. Blood cells, molecules & diseases

Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer

Artificial Super Neutrophils for Inflammation Targeting and HClO Generation against Tumors and Infections

Fabrication of Synthetic Mesenchymal Stem Cells for the Treatment of Acute Myocardial Infarction in Mice

Mechanobiological mimicry of helper T lymphocytes to evaluate cell-biomaterials crosstalk

Engineering Cellular Biosensors with Customizable Antiviral Responses Targeting Hepatitis B Virus

Persistent Symptoms in Patients After Acute COVID-19

Macroscale biomaterials strategies for local immunomodulation

Materials engineering for immunomodulation

The three R's of lung health and disease: repair, remodeling, and regeneration

The long-term impact of severe acute respiratory syndrome on pulmonary function, exercise capacity and health status

Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy

Long-term bone and lung consequences associated with hospitalacquired severe acute respiratory syndrome: a 15-year follow-up from a prospective cohort study

Long-term Pulmonary Consequences of Coronavirus Disease 2019 (COVID-19): What We Know and What to Expect

Temporal Changes of CT Findings in 90 Patients with COVID-19 Pneumonia: A Longitudinal Study

CT imaging and clinical course of asymptomatic cases with COVID-19 pneumonia at admission in Wuhan

Pulmonary fibrosis secondary to COVID-19: a call to arms?

Generation of human bronchial organoids for SARS-CoV-2 research. bioRxiv

Human organs-on-chips as tools for repurposing approved drugs as potential influenza and COVID19 therapeutics in viral pandemics. bioRxiv

Bioengineered in Vitro Tissue Model of Fibroblast Activation for Modeling Pulmonary Fibrosis

COVID-19: The Potential Treatment of Pulmonary Fibrosis Associated with SARS-CoV-2 Infection

Interleukin-11 is a therapeutic target in idiopathic pulmonary fibrosis

Therapeutically Effective Controlled Release Formulation of Pirfenidone from Nontoxic Biocompatible Carboxymethyl Pullulan-Poly(vinyl alcohol) Interpenetrating Polymer Networks

Hydrogel-based delivery of Il-10 improves treatment of bleomycin-induced lung fibrosis in mice

Programmable microencapsulation for enhanced mesenchymal stem cell persistence and immunomodulation

Immunomodulation by mesenchymal stem cells in treating human autoimmune disease-associated lung fibrosis

Mesenchymal Stem Cell Therapy for COVID-19: Present or Future

Monocyte-derived multipotent cell delivered programmed therapeutics to reverse idiopathic pulmonary fibrosis

Inflammation and cardiac remodeling during viral myocarditis

Adult murine cardiomyocytes exhibit regenerative activity with cell cycle reentry through STAT3 in the healing process of myocarditis

COVID-19 cardiac injury: Implications for long-term surveillance and outcomes in survivors

COVID-19 and Multiorgan Response

Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19)

Toward Regeneration of the Heart: Bioengineering Strategies for Immunomodulation

Controlled dual delivery of fibroblast growth factor-2 and Interleukin-10 by heparin-based coacervate synergistically enhances ischemic heart repair

IL-33 enhances macrophage M2 polarization and protects mice from CVB3-induced viral myocarditis

Engineering Immunomodulatory Biomaterials for Regenerating the Infarcted Myocardium

B Cells Increase Myocardial Inflammation by Suppressing M2 Macrophage Polarization in Coxsackie Virus B3-Induced Acute Myocarditis

Modulation of subsets of cardiac B lymphocytes improves cardiac function after acute injury

The adaptive immune response to cardiac injury-the true roadblock to effective regenerative therapies?

Cardiac Autoimmunity: Myocarditis

Recognizing COVID-19-related myocarditis: the possible pathophysiology and proposed guideline for diagnosis and management

Silencing the CSF-1 Axis Using Nanoparticle Encapsulated siRNA Mitigates Viral and Autoimmune Myocarditis

Live imaging of wound angiogenesis reveals macrophage orchestrated vessel sprouting and regression

The role of macrophage phenotype in vascularization of tissue engineering scaffolds

Treating ischemia via recruitment of antigen-specific T cells

Long-Term Neurological Threats of COVID-19: A Call to Update the Thinking About the Outcomes of the Coronavirus Pandemic

Sofosbuvir protects human brain organoids against SARS-CoV-2. bioRxiv

Depression as a Mediator of Chronic Fatigue and Post-Traumatic Stress Symptoms in Middle East Respiratory Syndrome Survivors

Chronic widespread musculoskeletal pain, fatigue, depression and disordered sleep in chronic post-SARS syndrome; a casecontrolled study

Impact of SARS-CoV-2 infection on neurodegenerative and neuropsychiatric diseases: a delayed pandemic

Coronaviruses and Central Nervous System Manifestations

Sars-Cov-2: Underestimated damage to nervous system

Beyond immunomodulation: The regenerative role for regulatory T cells in central nervous system remyelination

M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination

Myelin repair in vivo is increased by targeting oligodendrocyte precursor cells with nanoparticles encapsulating leukaemia inhibitory factor (LIF)

2020) A materials-science perspective on tackling COVID-19

Mechanisms underlying T cell ageing

Seasonal coronavirus protective immunity is short-lasting

2020) T cell epitope predictions

Epitope-based peptide vaccines predicted against novel coronavirus disease caused by SARS-CoV-2

The significance of artificial intelligence in drug delivery system design

Knowledge gaps in immune response and immunotherapy involving nanomaterials: Databases and artificial intelligence for material design

This work is supported in part by grants from National Institute of Health 

All authors made substantial contributions to the content, writing, and editing of the manuscript. Figures were designed by J.Z.

The authors declare no competing interests.J o u r n a l P r e -p r o o f